【12 月 4 日,科伦博泰生物核心产品芦康沙妥珠单抗在中国获批上市,用于治疗 2L 及以上三阴性乳腺癌,系国内首个获批的国产 TROP2ADC】中金发表报告称,本次批准基于国内三期临床试验 OptiTROP-Breast01 的积极结果。据 2024 年 ASCO 上公司披露的中期分析数据,与化疗相比,sac-TMT 在患者无进展生存期和总生存期方面均有显著统计学意义和临床意义的改善,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.